SR One co-led a round that included Celgene and Alexandria Venture Investments, as Gotham Therapeutics came out of stealth.

US-based biotechnology startup Gotham Therapeutics emerged from stealth yesterday with $54m in a series A round co-led by SR One, the strategic investment arm of pharmaceutical firm GlaxoSmithKline. The round was co-led by investment firm Versant Ventures and venture capital firm Forbion, and included pharmaceutical company Celgene and Alexandria Venture Investments, the VC arm of…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.